Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Schrodinger, Inc. - Common Stock (NQ:SDGR)

17.20 -0.44 (-2.48%)
Streaming Delayed Price Updated: 2:38 PM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Schrodinger, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures
A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as... 
Via TokenRing AI
Topics Artificial Intelligence Climate Change Intellectual Property
News headline image
AI Unlocks Cosmic Secrets: Revolutionizing Discovery in Physics and Cosmology
Artificial Intelligence (AI) is ushering in an unprecedented era of scientific discovery, fundamentally transforming how researchers in fields like cosmology and physics unravel the universe's most... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Schrodinger ↗
 
Via Benzinga
Schrodinger Downgraded By Citi After Ending Blood Cancer Drug Trial Tied To 2 Deaths; Retail Voices Concern ↗
Via Stocktwits
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors
As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for... 
Via MarketMinute
Topics Artificial Intelligence Climate Change Economy
News headline image
Expert Outlook: Schrodinger Through The Eyes Of 5 Analysts ↗
 
Via Benzinga
Schrödinger Discontinues Clinical Program After Two Patient Deaths ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 26, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Lilly's AI Gambit: TuneLab Poised to Reshape Biotech Drug Discovery Landscape
Eli Lilly and Company (NYSE: LLY) has unveiled its groundbreaking TuneLab Platform, an artificial intelligence (AI) and machine learning (ML) initiative designed to democratize advanced drug discovery... 
Via MarketMinute
Topics Animal Testing Artificial Intelligence Intellectual Property
News headline image
This Cisco Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
This AZZ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy... 
Via MarketMinute
Topics Artificial Intelligence Economy Emissions
News headline image
Schrödinger (SDGR) Q2 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
3 Momentum Stocks That Could Soar Post-Market Volatility
Three unexpected companies have rallied quickly in the period following tariff-related market turbulence; can they maintain momentum? 
Via MarketBeat
Topics Artificial Intelligence World Trade
News headline image
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing ↗
FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods. 
Via Benzinga
Topics Animal Testing
News headline image
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
Wondering what's happening in today's after-hours session? ↗
The regular session of the US market on Thursday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
News headline image
Health Care Technology Stocks Surge After FDA Announces Plans To Phase Out Animal Testing Requirements ↗
Several stocks in the health care technology space are moving higher after the market close on Thursday after the U.S. Food and Drug Administration (FDA) announced plans to phase out animal testing... 
Via Benzinga
Topics Animal Testing
News headline image
AI Pharma: 2 Paths to AI-Powered Drug Investment
AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Seagate Posts Upbeat Earnings, Joins Netflix, Travelers, Teledyne Technologies And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details ↗
Schrödinger shares rise as they announce a research partnership and licensing agreement with Novartis AG. Schrödinger will receive $150 million upfront and eligible to receive up to approximately $2.3... 
Via Benzinga
News headline image
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
News headline image
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
News headline image
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone! ↗
The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... 
Via Talk Markets
Topics Economy
News headline image
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week ↗
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.